reid huber  incyte corporation  zoominfocom bellicum appoints reid huber phd to board of directors  business wire bellicum appoints reid huber phd to board of directors november    am eastern standard time houstonbusiness wirebellicum pharmaceuticals inc a biopharmaceutical company focused on discovering and developing novel cellular immunotherapies today announced the appointment of reid m huber phd to its board of directors dr huber has over  years of experience in pharmaceutical research and clinical development in both senior leadership and scientific research positions he currently serves as executive vice president and chief scientific officer at incyte corporation where he leads drug discovery research primarily in the area of hematologyoncology “dr huber has an impressive track record of leading drug discovery research and a depth of knowledge and understanding of immunooncology that is central to several of bellicum’s clinical programs” commented tom farrell ceo of bellicum pharmaceuticals “we look forward to the unique perspective reid can bring to bellicum as we advance our novel cell therapy product candidates” added dr huber “i am eager to work closely with fellow bellicum directors and the management team in helping to achieve the full potential of the company’s promising controlledcell therapies” dr huber began his career at dupont pharmaceuticals in  and was a founding member of the team that started drug discovery at incyte corporation in  he received his bs in biochemistrymolecular genetics from murray state university and his phd in molecular genetics from washington university and later trained at the national institutes of health about bellicum pharmaceuticals bellicum is a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies for various forms of cancer including hematological cancers and solid tumors as well as orphan inherited blood disorders the company is using its proprietary chemical induction of dimerization or cid technology platform to engineer and control components of the immune system in real time the company is developing nextgeneration product candidates in some of the most important areas of cellular immunotherapy including hematopoietic stem cell transplantation or hsct car t cell therapy and dendritic cell vaccines for more information please visit wwwbellicumcom contacts investorspete rahmer prahmertroutgroupcomormediabrad miles bmilesbmccommunicationscomoramy bonanno abonannobmccommunicationscom contacts investorspete rahmer prahmertroutgroupcomormediabrad miles bmilesbmccommunicationscomoramy bonanno abonannobmccommunicationscom search advanced news search advanced news search log in sign up insider trading  huber reid m  form  sec filings home  archives  products  about  contact  faq  new user sign up  sign in form  filings insider buys significant buys penny stocksinsider buying insider sales insider buy sell ratios stock options insider tradingstock screener insider tradinggraph view insider watch sec filings insider trading  huber reid m select time period  month  months  months  months  year  years  years  years all data       google     yahoo send this page to   blog    digg    reddit    facebook    stumble    delicious enter stock ticker symbol or cik cik lookup search by company or insider name insiders might sell their shares for any number of reasons but they buy them for only one they think the price will rise  peter lynch  what is insider trading email a friend  historical filings delayed by  months new user sign up for real time data existing user sign in common stock purchase or sale transactiondate reporteddate company symbol insiderrelationship sharestraded averageprice totalamount sharesowned filing sale  pm incyte corp incy huber reid mevp chief scientific officer    direct view sale  pm incyte corp incy huber reid mevp chief scientific officer    direct view sale  pm incyte corp incy huber reid mevp chief scientific officer    direct view sale  pm incyte corp incy huber reid mevp chief scientific officer    direct view sale  pm incyte corp incy huber reid mevp chief scientific officer    direct view stock options exercise award grant conversion transactiondate reporteddate exercisableexpiration company symnbol insiderrelationship sharestraded conversionprice sharesowned filing exercise  pm nana incyte corp incy huber reid mevp chief scientific officer   direct view exercise  pm na incyte corp incy huber reid mevp chief scientific officer   direct view option award  pm nana incyte corp incy huber reid mevp chief scientific officer   direct view option award  pm na incyte corp incy huber reid mevp chief scientific officer   direct view option award  pm na bellicum pharmaceuticals inc blcm huber reid mdirector   direct view exercise  pm nana incyte corp incy huber reid mevp chief scientific officer   direct view exercise  pm na incyte corp incy huber reid mevp chief scientific officer   direct view option award  pm nana incyte corp incy huber reid mevp chief scientific officer   direct view option award  pm na incyte corp incy huber reid mevp chief scientific officer   direct view option award  pm na incyte corp incy huber reid mevp chief scientific officer   direct view option award  pm na incyte corp incy huber reid mevp chief scientific officer   direct view option award  pm na incyte corp incy huber reid mevp chief scientific officer   direct view exercise  pm nana incyte corp incy huber reid mevp chief scientific officer   direct view exercise  pm na incyte corp incy huber reid mevp chief scientific officer   direct view exercise  pm nana incyte corp incy huber reid mevp chief scientific officer   direct view exercise  pm nana incyte corp incy huber reid mevp chief scientific officer   direct view exercise  pm na incyte corp incy huber reid mevp chief scientific officer   direct view exercise  pm na incyte corp incy huber reid mevp chief scientific officer   direct view option award  pm na bellicum pharmaceuticals inc blcm huber reid mdirector   direct view exercise  pm nana incyte corp incy huber reid mevp chief scientific officer   direct view exercise  pm nana incyte corp incy huber reid mevp chief scientific officer   direct view exercise  pm nana incyte corp incy huber reid mevp chief scientific officer   direct view exercise  pm na incyte corp incy huber reid mevp chief scientific officer   direct view exercise  pm na incyte corp incy huber reid mevp chief scientific officer   direct view exercise  pm na incyte corp incy huber reid mevp chief scientific officer   direct view exercise  pm nana incyte corp incy huber reid mevp chief scientific officer   direct view exercise  pm nana incyte corp incy huber reid mevp chief scientific officer   direct view exercise  pm na incyte corp incy huber reid mevp chief scientific officer   direct view exercise  pm na incyte corp incy huber reid mevp chief scientific officer   direct view   secformcom all rights reserved archives        fri  jul    sec is the us securities and exchange commission edgar is a trademark of the sec secformcom is not affiliated with or approved by the us securities and exchange commission sec terms of use  privacy statement  reid m huber incyte corporation chief scientific officer  evp  redbooks brands marketers agencies search less sell more    sign in get a free trial    contact us   reid m huber chief scientific officer  evp incyte corporation email realtime sales trigger feed  generated by redbooks machine learning and natural language processing technology tracking  news sources to aggregate all new executives jobrole changes and news on decision makers brands and agencies in the mediamarketing industry this sales feed is for reid m huber at incyte corporation reid m huber works as chief scientific officer  evp  incyte corporation is a leader in pharmaceuticals  health care products  redbooks tracks personnel changes for advertisers spending over  million annually for more leads or mediamarketing prospecting automation start a free trial now recent related news  innovation delaware company to watch incyte  what started as work toward a way to combat multiple myeloma and other tumors eventually became a pharmaceutical that tackled myelofibrosis and polycythemia vera two blood cancers “those were two diseases we didn’t consider when we started” says reid huber phd incyte’s chief scientific officer “so with the research we are doing in  we have to have an eye on  and  people in this article reid m huber  incyte incy q  results  earnings call transcript  its steven again i will do your first question and then ill ask reid huber to address your second question about lsd in sickle cell in terms of the reach studies in general and the use of glucocorticoid as a standard initial therapy the most common used is methylprednisolone is usually used at a dose of  milligrams per kilogram in divided doses  people in this article michael booth  reid m huber learn more about reid m huber and  key contacts   create targeted lead lists   gain insider knowledge with advanced machine  learning   realtime verified contact info enter work email please enter email address please enter valid email address learn more about reid m huber and  key contacts first name  please enter first name last name  please enter last name company name  please enter company name email  phone  please enter phone number please enter  digits number what industry are you in    please select one the categories below please enter value for the industry  media sales  production  adtechmartech  sponsorship sales   agency new business   other what is your role    please select one the categories below please enter value for the role   csuite   vpmanager   sales rep   other thank you for registering for a free redbookscom trial we are processing your request and will be in touch shortly to get you started for immediate assistance please call us at   or email us at inforedbookscom home learn more free trial features ad think events thought leadership events top advertiser directory top agency directory add your agency update your agency agency showcase advertising associations creative spotlight services and suppliers about us blog contact us jobs terms  conditions privacy policy customer support   connect with us copyright   red books llc all rights reserved microsoft personalized ad preferences to opt out of personalized ads in this browser your browser history must allow firstparty and thirdparty cookies and you must have your browsing experience set to not delete browsing history on exit instructions for enabling cookies and configuring your browsing history may be available in your browsers settings privacy or help documentation sign in hold on… we’re sorry but this didn’t work you can’t turn off personalized ads right now because your browser is currently blocking thirdparty cookies we can help you fix this issue let’s get started depending on what browser you use open options or settings make sure that thirdparty cookies are not blocked anymore to find out how search your browser’s help revisit httpchoicemicrosoftcomoptout and then on the “personalized ads in this browser” tile click off ext about our ads to create a more customized online experience some of the ads you may receive on microsoft websites and apps are tailored to your previous activities searches and site visits youre in control and heres where you can make the advertising choice thats right for you ext where can i learn more about advertising on microsoft websites and apps microsoft partners with oath appnexus and other third party service providers to help present customized content and display advertisements on msn outlookcom and other websites and apps microsoft also delivers search ads to bing and our search syndication partners learn more about microsoft’s privacy practices here you can learn more about interestbased ads from oath and appnexus in their privacy statements oath and appnexus what choices do i have about interestbased advertising on this page you can opt out of receiving interest based advertising from microsoft you can also opt out of receiving interestbased advertising from all selfregulatory members including microsoft oath appnexus and other third party ad networks at the following sites in the us digital advertising alliance daa in europe european interactive digital advertising alliance edaa in canada ad choices digital advertising alliance of canada daac you can control interestbased advertising in windows apps by turning off the advertising id in windows settings more choices do you want personalized ads from other companies questions if you have a privacy question or a question for the chief privacy officer of microsoft please contact us by using our web form we will respond to questions within  days ext personalized ads in this browser off optout is currently unavailable please try again later control the personalized ads setting for this web browser learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off ext personalized ads wherever i use my microsoft account off sign in to change optout is currently unavailable please try again later control the personalized ads setting that applies when you are signed in on any computer or device with your microsoft account including windows windows phone xbox and other devices learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off if you choose “generic” ads and use a browser your choice applies to everyone when using that browser as long as you do not clear your cookies ext personalized ads in windows in your windows settings you can turn off personalized ads that appear in apps on this device you’ll still see ads but they won’t be personalized anymore if you have windows  access the charms by touching or moving your pointer to the right edge of the screen click or tap settings and then click or tap change pc settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have windows  click or tap the start button click or tap settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have a windows mobile device go to settings tap on privacy tap on advertising id and then turn off let apps use my advertising id for experiences across apps if you want to turn off personalized ads from microsoft wherever you use your microsoft account including apps on windows windows phone xbox and other devices you can do so by selecting the microsoft account option above ext legal privacy  cookies   microsoft incyte corp  incy stock price quote at ally invest quotes snapshot  incyincyte corp incynasdaqset alertoptionsstreaming charts next earnings date is expected on  last pricenasdaq previous close  last trade as of pm et todays changebid size ask size day low  high  volume ksellbuysnapshotchartsnewsoptionsearningsfundamentalsfinancialsinsiders view advanced chart mountain ohlc candlestick line chart style download historical data   view biotechnology industrypeer comparison as of  day day month month year year yeartimeframe incyte corp  nasdaq price change  volume  kpm et  sellbuydetailed quoteset alertoptions chain illumina inc  nasdaq price change  volume  kpm et  sellbuydetailed quoteset alertoptions chain alexion pharmaceuticals inc  nasdaq price change  volume  mpm et  sellbuydetailed quoteset alertoptions chain na  na price nachange na navolume nana sellbuydetailed quoteset alertoptions chain agilent technologies inc  nyse price change  volume  mpm et  sellbuydetailed quoteset alertoptions chain read more news recent news eli lilly and incytes resubmission of a new drug application to the fda will be delayed beyond am et  benzingaeli lilly and company nyselly and incyte corporationlilly and incyte provide update on baricitinibam et  prnewswire indianapolis july   prnewswire  eli lilly andincyte reports first patient was treated in phase  trial of itacitinib for acute graftversushost diseaseam et  benzinga  benzingacom benzinga does not provide investment advice all rights reservedmerus announces first quarter  financial results and midyear operating resultspm et  globe newswirebalance sheet strengthened with  million upfront payment and an  million share purchase from incyte corporation for global strategic research collaboration to discover view all commentary and analysis  things in biotech you should learn today july  am et  seeking alphabiotech bonanza the next leg uppm et  seeking alpha things in biotech you should learn today july  am et  seeking alphafdas flashing green light boosts novel drug approvalspm et  seeking alpha company profile business descriptionincyte corp is a biopharmaceutical company which focuses on the discovery development development formulation manufacturing and commercialization of proprietary therapeutics to treat serious unmet medical needs primarily in oncology its product jakafi a jak and jak inhibitor is currently approved in the us for the treatment of intermediate or highrisk myelofibrosis and is in development as a potential treatment for other cancers the companywas founded by roy a whitfield in april  and is headquartered in wilmington de view company web site for more detailsaddress augustine cutoffwilmington delaware phonenumber of employeesrecent sec filing chairman president  chief executive officerhervé hoppenotchief financial officer  executive vice presidentdavid w gryskachief scientific officer  executive vpreid m huberchief medical officer  executive vice presidentsteven h stein company highlights price openprevious close week range  market capitalization bshares outstanding msectorhealth technologyindustrybiotechnologynext earnings announcement options summary call open interest dput open interest dcall volume dput volume dput call open interest ratio dput call volume ratio d data delayed by up to  minutes view all fundamentalsfundamentals price  earningsnaearnings per sharebeta vs sp revenue bnet profit marginreturn on equity analyst ratings as of buyoverweightholdunderweightsellconsensus recommendationpowered by factset   reid m huber of incyte corp executive profile   welcome company news company site premium log in membership home portfolio stocks bonds funds etfs cef markets tools real life finance discuss investing ideas fund analyst picks picks by category fund pick performance picks  pans enewsletter fund spy column fund spy book bond squad fund video reports fundinvestor newsletter etf investing fund family experts fund reports all fund analyst reports fund stewardship reports fund ratings highestrated value highestrated growth highestrated largecap highestrated midcap highestrated smallcap foreign fund standouts star rating performance rating methodology fund performance top month performers top ytd performers top year performers top year performers top year performers fund category returns biggest daily nav changes closedend funds exchangetraded funds quarterly market outlook fund screeners basic screeners fund screener longterm winners solid smallgrowth funds conservative bond funds premium screeners premium fund screener index funds hidden gems lowerrisk foreign funds video center incyte corp  incy morningstar rating add to portfolioget email alertsprint this pagepdf reportdata questionquotechartstock analysisperformancekey ratiosfinancialsvaluationinsidersownershipfilingsbondsoverviewexecutive compensationinsider activitykey executivesboard of directorscommittees key executives  reid m huber reid m huber executive vice president and chief scientific officer profile connections biography reid m huber age  has served as executive vice president chief scientific officer since april  dr huber joined incyte as associate director applied technology in january  and held roles of increasing responsibility in both drug discovery and clinical development at incyte prior to joining incyte dr huber held scientific research positions with dupont pharmaceuticals company from  to  dr huber held intramural predoctoral and postdoctoral fellowships at the national institutes of health from  dr huber received his bs in biochemistrymolecular genetics from murray state university and his phd in molecular genetics from washington university board membership reid m huber is not a member of any boards   we value your feedback let us know what you think site directory site map our products corrections help advertising opportunities licensing opportunities glossary rss mobile portfolio affiliate careers international sites australia canada china france germany hong kong italy the netherlands norway spain uk switzerland stocks by name  ticker  star rating  market cap  stock type  sector  industry mutual funds by star rating  investment style  total assets  category  top holdings  top sectors  symbol  ticker  name etfs by star rating  category  total assets  symbol  ticker  name articles by title  date  author  collection  interest  popularity investment categories by topic  sector  key indicators  user interest  market cap  industry premium stocks by name  ticker  star rating  market cap  stock type  sector  industry premium mutual funds by star rating  investment style  total assets  category  top holdings  top sectors  symbol  ticker  name premium etfs by star rating  category  total assets  symbol  ticker  name popular articles by title  date  author  collection  interest  popularity popular investment categories by topic  sector  key indicators  user interest  market cap  industry independent insightful trusted morningstar provides stock market analysis equity mutual fund and etf research ratings and picks portfolio tools and option hedge fund ira k and  plan research our reliable data and analysis can help both experienced enthusiasts and newcomers  copyright morningstar inc all rights reserved please read our terms of useand privacy policydow jones industrial average sp  nasdaq and morningstar index market barometer quotes are realtime russell  quote is  minutes delayed bellicum appoints reid huber phd to board of directors  bellicum pharmaceuticals inc smart weapons for the fight against cancer search for about us overview management team board of directors clinical advisory board careers contact us product candidates pipeline bpx bpx bpx cd program technology overview caspacide gocart scientific literature abstracts  presentations clinical trials bpx in blood cancers inherited blood disorders investors  media investor center home news  events press releases events  presentations stock information stock quote stock chart historic stock lookup analyst coverage investment calculator financial information annual reports  proxies sec filings corporate governance documents  charters management team board of directors committee composition shareholder services investor faq contact investor relations search for about us overview management team board of directors clinical advisory board careers contact us product candidates pipeline bpx bpx bpx cd program technology overview caspacide gocart scientific literature abstracts  presentations clinical trials bpx in blood cancers inherited blood disorders investors  media investor center home news  events press releases events  presentations stock information stock quote stock chart historic stock lookup analyst coverage investment calculator financial information annual reports  proxies sec filings corporate governance documents  charters management team board of directors committee composition shareholder services investor faq contact investor relations home » press releases » bellicum appoints reid huber phd to board of directors press releases scientific literature abstracts  presentations bellicum appoints reid huber phd to board of directors press releases houston tx november   –bellicum pharmaceuticals inc a biopharmaceutical company focused on discovering and developing novel cellular immunotherapies today announced the appointment of reid m huber phd to its board of directors dr huber has over  years of experience in pharmaceutical research and clinical development in both senior leadership and scientific research positions he currently serves as executive vice president and chief scientific officer at incyte corporation where he leads drug discovery research primarily in the area of hematologyoncology “dr huber has an impressive track record of leading drug discovery research and a depth of knowledge and understanding of immunooncology that is central to several of bellicum’s clinical programs” commented tom farrell ceo of bellicum pharmaceuticals “we look forward to the unique perspective reid can bring to bellicum as we advance our novel cell therapy product candidates” added dr huber “i am eager to work closely with fellow bellicum directors and the management team in helping to achieve the full potential of the company’s promising controlledcell therapies” dr huber began his career at dupont pharmaceuticals in  and was a founding member of the team that started drug discovery at incyte corporation in  he received his bs in biochemistrymolecular genetics from murray state university and his phd in molecular genetics from washington university and later trained at the national institutes of health about bellicum pharmaceuticals bellicum is a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies for various forms of cancer including hematological cancers and solid tumors as well as orphan inherited blood disorders the company is using its proprietary chemical induction of dimerization or cid technology platform to engineer and control components of the immune system in real time the company is developing nextgeneration product candidates in some of the most important areas of cellular immunotherapy including hematopoietic stem cell transplantation or hsct car t cell therapy and dendritic cell vaccines for more information please visit wwwbellicumcom reid m huber phd  bellicum pharmaceuticals inc smart weapons for the fight against cancer search for about us overview management team board of directors clinical advisory board careers contact us product candidates pipeline bpx bpx bpx cd program technology overview caspacide gocart scientific literature abstracts  presentations clinical trials bpx in blood cancers inherited blood disorders investors  media investor center home news  events press releases events  presentations stock information stock quote stock chart historic stock lookup analyst coverage investment calculator financial information annual reports  proxies sec filings corporate governance documents  charters management team board of directors committee composition shareholder services investor faq contact investor relations search for about us overview management team board of directors clinical advisory board careers contact us product candidates pipeline bpx bpx bpx cd program technology overview caspacide gocart scientific literature abstracts  presentations clinical trials bpx in blood cancers inherited blood disorders investors  media investor center home news  events press releases events  presentations stock information stock quote stock chart historic stock lookup analyst coverage investment calculator financial information annual reports  proxies sec filings corporate governance documents  charters management team board of directors committee composition shareholder services investor faq contact investor relations home » team members » reid m huber phd overview management team board of directors clinical advisory board careers contact us reid m huber phd director reid huber has over  years of experience in pharmaceutical research and clinical development in both senior leadership and scientific research positions he currently serves as executive vice president and chief scientific officer at incyte corporation where he leads drug discovery research primarily in the area of hematologyoncology dr huber began his career at dupont pharmaceuticals in  and was a founding member of the team that started drug discovery at incyte corporation in  he received his bs in biochemistrymolecular genetics from murray state university and his phd in molecular genetics from washington university and later trained at the national institutes of health